GRIN1 and Cognitive impairment: Emerging evidence suggests a potential role of NMDAR1 antibodies (NMDAR1-abs) as biomarkers for identifying patients at increased risk, particularly for neuropsychiatric sequelae such as cognitive impairment [10].